TY - JOUR ID - 29933 TI - Comprehensive Analysis of Temozolomide Treatment for Patients with Glioma JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 Y1 - 2014 PY - 2014 VL - 15 IS - 19 SP - 8405 EP - 8408 KW - Glioma KW - temozolomide chemotherapy KW - Efficacy KW - Toxicity DO - N2 - Background: This analysis was conducted to evaluate the efficacy and safety of temozolomide basedchemotherapy in treating patients with glioma. Methods: Clinical studies evaluating the efficacy and safety oftemozolomide based regimens for patients with glioma were identified using a predefined search strategy. Pooledresponse rates (RRs) were calculated. Results: In temozolomide based regimens, 5 clinical studies including 152patients with advanced glioma were considered eligible for inclusion. Four clinical studies included temozolomide.Systematic analysis suggested that, in all patients, pooled CR was 21% (32/152) , and PR was 21% (32/152).Grade 3/4 toxicity included neutropenia, thrombocytopenia, and anemia. No grade 3 or 4 renal or liver toxicitywas observed. No treatment related death occurred with temozolomide based treatment. Conclusion: Thissystematic analysis suggests that temozolomide based regimens are associated with mild response rate andacceptable toxicity for treatment of glioma patients. UR - https://journal.waocp.org/article_29933.html L1 - https://journal.waocp.org/article_29933_c1a8e24ac99282815a04bb3869db42d1.pdf ER -